1383450-81-4|JNJ-678|JNJ-678|MFCD30489307-范德生物科技公司

JNJ-678

NMR下载 COA and HPLC MSDS下载
names：
JNJ-678
CAS号：
1383450-81-4
MDL Number： MFCD30489307
MF(分子式)： C21H20ClF3N4O3S MW(分子量)： 500.92
EINECS:No data available Reaxys Number:No data available
Pubchem ID:118892432 Brand:BIOFOUNT

JNJ-678 (1383450-81-4,JNJ-53718678) 是新型融合蛋白 (fusion protein) 抑制剂，有潜力用于呼吸道合胞病毒 (RSV)的研究。

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
YZM000872-10mg	10mg	98%	¥ 7594.00	¥ 7594.00		2-3天	- +	¥ 0.00
YZM000872-5mg	5mg	98%	¥ 4488.00	¥ 4488.00		2-3天	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	JNJ-678(1383450-81-4);JNJ-53718678;Rilematovir
英文别名	JNJ-678(1383450-81-4)
CAS号	1383450-81-4
SMILES	O=C(N1CC(F)(F)F)N(CC(N2CCCS(=O)(C)=O)=CC3=C2C=CC(Cl)=C3)C4=C1C=CN=C4
Inchi	InChI=1S/C21H20ClF3N4O3S/c1-33(31,32)8-2-7-27-16(10-14-9-15(22)3-4-17(14)27)12-28-19-11-26-6-5-18(19)29(20(28)30)13-21(23,24)25/h3-6,9-11H,2,7-8,12-13H2,1H3
InchiKey	GTQTUABHRCWVLL-UHFFFAOYSA-N
分子式 Formula	C21H20ClF3N4O3S
分子量 Molecular Weight	500.92
闪点 FP	360.5±31.5 °C
熔点 Melting point	No data available
沸点 Boiling point	672.5±55.0 °C at 760 mmHg
Polarizability极化度	47.3±0.5 10-24cm3
密度 Density	1.5±0.1 g/cm3
蒸汽压 Vapor Pressure	0.0±2.1 mmHg at 25°C
溶解度Solubility	生物体外In Vitro:DMSO溶解度65 mg/mL(129.76 mM;Need ultrasonic)H2O< 0.1 mg/mL(insoluble)
性状	白色至灰白色固体粉末
储藏条件 Storage conditions	-20°C 3 years年 4°C 2 years年 / 溶液中:-80°C 6 months月 -20°C 1 month月

JNJ-678 (1383450-81-4,JNJ-53718678)实验注意事项：
1.实验前需戴好防护眼镜，穿戴防护服和口罩，佩戴手套，避免与皮肤接触。
2.实验过程中如遇到有毒或者刺激性物质及有害物质产生，必要时实验操作需要手套箱内完成以免对实验人员造成伤害
3.实验后产生的废弃物需分类存储，并交于专业生物废气物处理公司处理，以免造成环境污染

JNJ-678 (1383450-81-4,JNJ-53718678) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:JNJ-678 (1383450-81-4,JNJ-53718678),NJ-678试剂,NJ-678抑制剂,NJ-678的生产,NJ-678的纯度,NJ-678的作用,NJ-678的含量,NJ-678的使用,NJ-678的合成,NJ-678的MSDS,NJ-678的价格,NJ-678的外观,NJ-678的溶解度

产品说明	JNJ-678 (1383450-81-4,JNJ-53718678) 是新型融合蛋白的抑制剂，临床试验中用于治疗呼吸道合胞病毒 (RSV)
Introduction	JNJ-678 (1383450-81-4,JNJ-53718678) is a novelfusion proteininhibitor in clinical trials for the treatment of respiratory syncytial virus (RSV).
Application1
Application2
Application3

警示图
危险性	warning
危险性警示	Not available
安全声明	H303吞入可能有害+H313皮肤接触可能有害+H2413吸入可能对身体有害
安全防护	P264处理后彻底清洗+P280戴防护手套/穿防护服/戴防护眼罩/戴防护面具+P305如果进入眼睛+P351用水小心冲洗几分钟+P338取出隐形眼镜（如果有）并且易于操作,继续冲洗+P337如果眼睛刺激持续+P2393获得医疗建议/护理
备注	实验过程中防止吸入、食入，做好安全防护

Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference PMID 30974127; Antiviral research 2019 07; 167(?):45-67 (Review Article)

Integrating Duodenal Sampling in a Human Mass Balance Study to Quantify the Elimination Pathways of JNJ-53718678, a Respiratory Syncytial Virus Fusion Protein Inhibitor PMID 31832988;

A human challenge model for respiratory syncytial virus kinetics, the pharmacological effect of a novel fusion inhibitor, and the modelling of symptoms scores

Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor PMID 28761099; Nature communications 2017 08; 8(1):167

Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference PMID 30974127; Antiviral research 2019 07; 167(?):45-67 (Review Article)

Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor
Abstract:Respiratory syncytial virus is a major cause of acute lower respiratory tract infection in young children, immunocompromised adults, and the elderly. Intervention with small-molecule antivirals specific for respiratory syncytial virus presents an important therapeutic opportunity, but no such compounds are approved today. Here we report the structure of JNJ-53718678 bound to respiratory syncytial virus fusion (F) protein in its prefusion conformation, and we show that the potent nanomolar activity of JNJ-53718678, as well as the preliminary structure-activity relationship and the pharmaceutical optimization strategy of the series, are consistent with the binding mode of JNJ-53718678 and other respiratory syncytial virus fusion inhibitors. Oral treatment of neonatal lambs with JNJ-53718678, or with an equally active close analog, efficiently inhibits established acute lower respiratory tract infection in the animals, even when treatment is delayed until external signs of respiratory syncytial virus illness have become visible. Together, these data suggest that JNJ-53718678 is a promising candidate for further development as a potential therapeutic in patients at risk to develop respiratory syncytial virus acute lower respiratory tract infection.Respiratory syncytial virus causes lung infections in children, immunocompromised adults, and in the elderly. Here the authors show that a chemical inhibitor to a viral fusion protein is effective in reducing viral titre and ameliorating infection in rodents and neonatal lambs.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开